J

Johnson & Johnson

Makes prescription drugs and medical devices

National Sales Director Lung

Full-TimeDeadline 10/24/26
No salary listed
Expert
Bachelor's
Horsham, PA, USA
Hybrid
Sales & Account ManagementField Sales

About the job

Requirements
  • A bachelor's degree is required; an advanced degree is preferred.
  • At least 10 years of commercial experience within the pharmaceutical, biotechnology, healthcare, or a related industry.
  • At least 8 years of people leadership experience, including demonstrated success leading, coaching, and developing high-performing teams and leadership talent.
  • Proven experience developing and executing sales and commercial strategy, translating strategy into field execution, and delivering strong business results.
  • Demonstrated success leading and influencing within a complex, matrixed organization.
  • Deep customer orientation and experience leveraging customer insights, market intelligence, and an outside-in perspective to inform commercial strategy and execution.
  • Strong understanding of the U.S. healthcare system and evolving market dynamics impacting customer engagement, access, and adoption.
  • Demonstrated ability to leverage data, analytics, market intelligence, and AI-enabled solutions to generate insights, inform decisions, and improve commercial execution.
  • Experience partnering cross-functionally across Sales, Marketing, Market Access, Strategic Accounts, and other commercial functions.
  • Demonstrated experience successfully leading through complex business, organizational, and talent situations.
Responsibilities
  • Lead the development and execution of the national sales strategy to drive market access, adoption, demand, and revenue.
  • Translate brand strategy and market intelligence into clear field priorities and disciplined execution.
  • Lead sales planning and execution, ensuring the organization is positioned to meet or exceed business objectives.
  • Integrate customer insights and voice of the customer into commercial and brand strategy.
  • Identify opportunities to innovate and strengthen competitive performance in complex and evolving markets.
  • Maintain a deep understanding of customers, market dynamics, the U.S. healthcare environment, and evolving barriers to access and adoption.
  • Use market data, customer insights, and business intelligence to optimize targeting, resource allocation, and commercial execution.
  • Represent the field perspective in brand planning and longer-range commercial planning.
  • Build organizational capability to anticipate market changes and convert insights into action.
  • Lead, coach, and develop a high-performing and diverse sales organization.
  • Build a strong pipeline of future sales and commercial leaders.
  • Lead effectively through complex talent and organizational situations.
  • Create an environment that reinforces accountability, development, collaboration, and strong execution.
  • Cultivate talent and implement innovative approaches that support business growth and organizational adaptability.
  • Partner across Brand, Marketing, Market Access, Strategic Accounts, and other commercial functions to connect strategy with execution.
  • Influence within a highly matrixed environment and align stakeholders around business and customer priorities.
  • Bring field insights into strategic decision-making and help shape commercial priorities.
  • Demonstrate broad enterprise thinking beyond the immediate sales organization.
  • Leverage AI, market data, analytics, and advanced insights to strengthen targeting, decision-making, and field execution.
  • Champion appropriate use of AI-enabled solutions to convert insights into commercial strategies.
  • Build organizational capability to use data and technology to improve customer engagement and accelerate business results.
Desired Qualifications
  • Demonstrated breadth across multiple commercial leadership roles, therapeutic areas, or market environments.
  • Experience across more than one commercial discipline, such as Sales, Marketing, Market Access, Strategic Accounts, or Strategy & Operations.
  • Experience leading in launch, growth, and/or highly competitive market environments.
  • Strong understanding of brand finance, business planning, and longer-range commercial planning.
  • Demonstrated track record of developing current and pipeline talent and strengthening organizational capability.
  • Experience leading innovative commercial initiatives and translating customer and market insights into measurable business impact.
  • Experience building team AI literacy and confidence, reinforcing trusted and responsible AI use and sound judgment.
  • Demonstrated commitment to learning emerging technologies, such as AI, through exploration, iteration, and applying new tools over time.

About the company

Johnson & Johnson develops prescription medicines and makes medical devices for hospitals, and unlike most big drugmakers, it runs both businesses under one roof. In 2015, its Darzalex became the first antibody drug approved for multiple myeloma, a blood cancer. Its medicines treat cancer, immune diseases such as psoriasis, and mental illnesses such as depression, and patented drugs bring in most of its sales. Its MedTech unit makes heart pumps, catheters that treat irregular heartbeats, surgical sutures, and Acuvue contact lenses. It was founded in 1886 to make sterile surgical dressings, is based in New Brunswick, New Jersey, and spun off its consumer brands, such as Tylenol and Band-Aid, as Kenvue in 2023.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Cancer drugs drive growth: oncology sales rose 17% to $7.4 billion in the June 2026 quarter, 29% of the total.
  • Stock grants have gained value: J&J shares rose 58% in the year to September 2026, versus 23% for Pfizer.
  • Students have a way in: J&J listed 1,897 open jobs in October 2026, including 201 internships, co-ops and early-career roles.

What critics are saying

  • Its key immune drug trails: AbbVie's Skyrizi outsold Tremfya $5.5 billion to $2.0 billion in the June 2026 quarter.
  • Orthopedics is leaving J&J: in September 2026, it was negotiating a $20 billion sale to buyout firm Apollo.
  • Baby powder suits remain costly: in July 2026, J&J agreed to pay $5.5 billion to end about 76,000 cancer claims.

What makes Johnson & Johnson unique

  • Its debt is rated safer than America's: S&P's top AAA rating goes to only two US companies, J&J and Microsoft.
  • Employees rank above shareholders: J&J's 1943 Credo lists duties to patients, then staff and communities, with stockholders last.
  • Its psoriasis pill is a first: Icotyde, approved March 2026, blocks an immune signal rivals target only by injection.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Remote Work Options
  • Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-2%

1 year growth

-2%

2 year growth

-2%
Yahoo Finance
Oct 17th, 2026
Johnson & Johnson dips after $25.4B quarter: buy the Dividend King?

Johnson & Johnson shares fell after the healthcare group reported third-quarter results, despite a beat-and-raise quarter. Revenue rose 5.9% to $25.4 billion, while adjusted earnings per share fell 7.5% to $2.59, a drop attributed mostly to acquisitions. Innovative medicine sales rose 7.7% to $16.8 billion, led by cancer drug Darzalex ($4.2 billion) and Tremfya ($2.4 billion, up 68.3%). The company raised its 2026 operational sales guidance to $100.7 billion at the midpoint, from $100.6 billion. Medtech revenue grew just 2.5% to $8.6 billion, which drove the share dip. Safety and efficacy concerns over its Impella heart pumps hurt the cardiovascular unit abroad. The company has raised its dividend for 64 consecutive years, making it a Dividend King.

Yahoo Finance
Oct 14th, 2026
J&J shares fall 6% as MedTech sales miss forecasts despite $25.4B revenue beat

Johnson & Johnson shares fell 6% after its medical device sales missed forecasts, even though third-quarter results beat estimates. Revenue was $25.4 billion, above the $25.37 billion expected. Adjusted earnings were $2.59 per share, $0.07 above estimates. MedTech sales rose 2.5% to $8.6 billion, below the $8.71 billion forecast, and marked a second straight quarterly miss. The company blamed the Middle East conflict, European austerity, and pricing pressure in China. Pharmaceutical sales rose 7.7% to $16.76 billion. Net earnings fell to $210 million from $2.12 a year earlier, hit by about $7 billion in talc settlement and deal costs. The company raised its full-year sales outlook to about $101.2 billion and said it is leaning toward spinning off its orthopedics unit, DePuy Synthes, by mid-2027.

Yahoo Finance
Oct 13th, 2026
J&J medtech sales rise just 2.5% to $8.64B as Abiomed slump weighs on cardiovascular

Johnson & Johnson's medtech sales rose 2.5% year over year to $8.64 billion in the third quarter, missing internal expectations. Growth has slowed for two quarters in a row, after rising more than 7% in the first quarter and last year's fourth quarter. The cardiovascular unit grew 4.3% to $2.31 billion. Its Abiomed business, bought in 2022 for $16.6 billion, fell 2.3% to $412 million. Tim Schmid, worldwide chairman of medtech, blamed lower patient volume after an unfavourable UK study of the Impella heart device. He called the setback temporary and said pressure also came from sales outside the US. J&J expects results from its PROTECT IV study of nearly 1,300 patients next year.

Yahoo Finance
Oct 13th, 2026
Memory stocks slide on Chinese chip breakthrough as UnitedHealth and Goldman beat estimates

US stock futures were mixed on Tuesday as investors weighed a wave of earnings reports. Dow futures rose 0.9%, S&P 500 futures slipped 0.1%, and Nasdaq futures fell 0.7%. Memory stocks fell for a second day after a Chinese chipmaker, CXMT, said it had made a breakthrough in memory chip production. Roundhill Memory ETF fell more than 5% in premarket trading. UnitedHealth rose more than 2% after it earned an adjusted $4.69 per share on $112.69 billion in revenue, beating estimates. It raised its full-year earnings outlook to at least $20.50 per share. Goldman Sachs gained more than 3% on strong results. JPMorgan Chase, Wells Fargo, and Citigroup fell short in parts of their reports. Johnson & Johnson fell 2% after $25.40 billion in sales narrowly missed estimates, though it raised its full-year forecasts.

CNBC
Oct 13th, 2026
J&J beats estimates and lifts forecast to $101.2B, but Middle East conflict hurts device sales

Johnson & Johnson (J&J) beat earnings estimates, but the Middle East conflict hurt its medical-device sales in the region. Chief financial officer Joe Wolk said Gulf states such as Kuwait, the UAE, and Saudi Arabia are shifting budgets towards defence. The conflict has not yet raised J&J's costs. Tremfya sales rose 68% to $2.4 billion, beating estimates of about $2.19 billion. Stelara sales, which face generic competition, fell 54% to $716 million, above expectations of $591 million. Darzalex sales rose about 16% to $4.24 billion, short of the $4.4 billion expected. J&J raised its full-year sales forecast to about $101.2 billion at the midpoint, from $101.1 billion. Its adjusted earnings midpoint rose to $11.10 per share from $11.04. Shares closed at $263.73 on Monday, up 27% this year.